Clinical Trial Evaluating the Safety of the TQB2103 for Injection
NCT05867563
·
clinicaltrials.gov ↗
PHASE1
Phase
UNKNOWN
Status
71
Enrollment
INDUSTRY
Sponsor class
Conditions
Advanced Malignant Neoplasm
Interventions
DRUG:
TQB2103 for injection
Sponsor
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.